Evidence map›Paper›PMID 41311375›Full record

ArticleRespiratory medicine case reports2025

Rapid disease progression and hydrocephalus following tarlatamab therapy initiation: A case report.

Doppo Fukui, Jun Sakakibara-Konishi, Riku Azuma, Yukiko Yoshida, Daisuke Morinaga, Shotaro Ito, Megumi Furuta, Yuta Takasihma, Hidenori Kitai, Satoshi Konno

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Doppo FukuiDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Jun Sakakibara-KonishiDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Riku AzumaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Yukiko YoshidaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Daisuke MorinagaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Shotaro ItoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Megumi FurutaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Yuta TakasihmaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Hidenori KitaiDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
Satoshi KonnoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tarlatamab is a novel bispecific T-cell engager immunotherapy that has demonstrated efficacy against small-cell lung cancer (SCLC) in terms of noteworthy anticancer activity and survival outcomes. However, no studies have detailed the patterns of disease progression during tarlatamab treatment. Herein, we present a case of acute disease progression after tarlatamab initiation in a 71-year-old male patient with extensive-stage SCLC. Following tarlatamab administration, he developed symptoms of cognitive impairment, which raised suspicion of immune effector cell-associated neurotoxicity syndrome (ICANS), an adverse event associated with the drug. Diagnostic evaluation revealed that the symptoms were caused by obstructive hydrocephalus due to worsening brain metastases. Following tarlatamab administration, we observed rapid progression of the previously indolent SCLC, leading to deterioration in the patient's overall condition. This case highlights the need to consider the possibility of rapid disease progression following tarlatamab administration and underscores the importance of adequate assessment to exclude ICANS. Since rapid tumor progression may lead to a decline in the patient's general condition, careful follow-up is advised.

Indexed as

Extensive-stage small-cell lung cancerHydrocephalusHyperprogressive diseasePineal gland metastasisTarlatamab

Identifiers

PMID41311375
PMCPMC12648723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.